Reproductive Health

Kegg Unveils Study Showing Potential for Hormone-Free Birth Control Through Cervical Fluid Tracking

In a stride towards non-hormonal birth control methods, Lady Technologies, the company behind kegg, recently presented a new study at the 2023 meeting of the Society of Reproductive Investigation in San Francisco. The study represents a potential shift in the landscape of fertility monitoring, emphasizing the accuracy of cervical fluid tracking over the traditional method of basal body temperature (BBT) monitoring. The…

YourChoice Therapeutics Begins Landmark Trial for Hormone-Free Male Birth Control Pill

YourChoice Therapeutics, a pioneer in the field of male contraception, has announced the initiation of a phase one clinical trial for YCT-529, a groundbreaking male birth control pill. This development marks a significant advancement in contraceptive technology, offering a promising alternative to the limited options currently available to men. The trial commenced in San Francisco, with the first group of male volunteers…

New Study Funded by $3M Government Grant Explores Connection Between Genomics and IVF Outcomes

A $3 million grant from the federal government’s Medical Research Future Fund (MRFF) in Australia has been allocated to support a unique IVF study, a collaborative effort between Virtus Health, healthtech startup 23Strands, and Monash University. This study is the first of its kind, focusing on how whole genome sequencing can improve patient outcomes in IVF treatments. James Pyne, Virtus Health CEO…

Aditxt Enters Women’s Health Market with $100M Evofem Acquisition

Aditxt has entered into a definitive agreement to acquire Evofem Biosciences, known for its FDA-approved hormone-free contraceptive gel, Phexxi. The acquisition, valued at around $100 million, combines stock issuance and debt assumption. Evofem’s flagship product, Phexxi, offers a non-daily, hormone-free contraceptive choice, aligning with the trend towards personalized women’s healthcare. Despite financial challenges, reflected in a significant share price decline, Evofem reported…

Freya Biosciences Secures $38M in Series A Funding to Advance Women’s Reproductive Immunotherapies

Freya Biosciences, a clinical-stage biotech company, has raised $38M Series A funding to advance the development of innovative women’s reproductive immunotherapies. The funding round was led by Sofinnova Partners and OMX Ventures with participation from The Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family Office, CE-Ventures, Corundum Systems Biology, and Indaco Venture Partners. Freya Biosciences’ Series A comes on…

Imaware Acquires Binx Health’s Consumer Testing Business, Expanding its Reach in STI Health Screening

In a move within the home-testing healthcare market, imaware has announced the acquisition of binx health’s at-home consumer testing business. This acquisition marks a notable expansion in imaware’s operational scope, particularly in the field of sexually transmitted infection (STI) testing, an area where STIs are increasingly reported in the USA. The acquisition combines imaware’s digital health platform, which specializes in home-testing for…

Mosie Baby Achieves FDA Class II Clearance for At-Home Intravaginal Insemination Kit

Mosie Baby, an at-home fertility care company, has recently obtained FDA Class II clearance for its Mosie Baby Kit. This clearance positions the Mosie Baby Kit as the first and only over-the-counter option for intravaginal insemination (IVI) approved by the FDA. The kit was developed to help individuals and couples who face challenges with natural conception or for whom traditional intercourse is…

Metabolon Wins NIH Award to Develop Test to Improve PCOS Diagnostic Accuracy

Metabolon, recognized for its contributions in metabolomics, has recently been awarded a grant by the National Institute of Health (NIH). This funding will go towards the development of a more accurate diagnostic test for polycystic ovary syndrome (PCOS). An estimated 8-13% of women are affected by PCOS, yet up to 70% remain undiagnosed. Metabolon’s project, backed by the NIH grant, seeks to…